Tandem Diabetes Care (TNDM) Shares Outstanding (Diluted Average) (2018 - 2026)

Tandem Diabetes Care has reported Shares Outstanding (Diluted Average) for 9 years, with the latest figure at $68.4 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Diluted Average) rose 3.0% year-over-year to $68.4 million; the trailing twelve-month figure through Mar 2026 stood at $68.4 million (up 3.0% YoY), and the FY2024 full-year result was $66.2 million, up 1.83% from the prior year.
• Shares Outstanding (Diluted Average) for Q1 2026 stood at $68.4 million, up from $67.0 million in the prior quarter.
• The five-year high for Shares Outstanding (Diluted Average) was $68.4 million in Q1 2026, with the low at $63.9 million in Q1 2022.
• Historically, Shares Outstanding (Diluted Average) has averaged $65.4 million across 5 years, with a median of $65.1 million in 2023.
• Annual changes were most pronounced in 2022 — Shares Outstanding (Diluted Average) retreated 0.84% — and 2025, when it gained 3.16%.
• Tandem Diabetes Care's Shares Outstanding (Diluted Average) stood at $64.1 million in 2022, then climbed by 1.28% to $65.0 million in 2023, then rose by 1.83% to $66.2 million in 2024, then grew by 1.33% to $67.0 million in 2025, then increased by 2.02% to $68.4 million in 2026.
• The last three Shares Outstanding (Diluted Average) figures came in at $68.4 million (Q1 2026), $67.0 million (Q3 2025), and $67.0 million (Q2 2025), per Business Quant data.